Travere Therapeutics Inc (NAS:TVTX)
$ 6.31 -0.25 (-3.81%) Market Cap: 480.37 Mil Enterprise Value: 463.90 Mil PE Ratio: 0 PB Ratio: 6.51 GF Score: 58/100

Travere Therapeutics Inc at Piper Sandler Healthcare Conference Transcript

Dec 01, 2022 / 03:30PM GMT
Release Date Price: $19.54 (-2.93%)
Do Kim
Piper Sandler - Analyst

All right. Good morning, everyone. My name is Do Kim. I'm one of the biotech analysts here at Piper. Next up, we have Travere. It is my pleasure to welcome CFO, Chris Cline.

Maybe we could start, Chris, just with you providing a brief introduction to the company and the key milestones that we are looking forward to.

Chris Cline
Travere Therapeutics, Inc. - CFO

Yeah. That's great. First off, thanks, Do, and thanks to Piper for having us today. It's great to be here.

I will be making forward-looking statements. So for a full risk factors and disclosures, please see our SEC filings.

But as many of you know, at Travere, we are exclusively focused on delivering life-changing therapies to people living with rare disease, and really coming into a very exciting time for the company. And really that's led by the fact that we're preparing for multiple launches from our pipeline.

And the first of those is sparsentan for IGA nephropathy, and we're preparing for a PDUFA date coming up in February of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot